Symphogen
Dan Bach Kristensen has over 20 years of experience in the biopharmaceutical industry. Dan Bach started their career as a research associate at Hiroshima University in 1997 and also worked as a research scientist and project leader at Japan Science & Technology Corporation. In 2001, they joined MDS Proteomics and later moved to MDS Denmark in 2003 as a senior scientist. From 2004 to 2008, they served as a principal scientist at Maxygen, where they were responsible for developing and implementing analytical methods for protein drug products. Dan Bach then joined Takeda in 2008 as a senior pharmaceutical scientist, focusing on supporting late-stage development of biopharmaceutical products. Currently, they are the principal scientist at Symphogen, leading the MS lab and overseeing the characterization of cancer and immuno-oncology targets.
Dan Bach Kristensen completed their high school education at Frederiksværk Gymnasium from 1985 to 1988. Dan Bach then went on to pursue a Bachelor of Science in Chemistry and a Master of Science in Biology, specializing in protein chemistry, at Aarhus University from 1988 to 1996. Finally, they obtained their Ph.D. in Biology with a focus on protein chemistry from Hiroshima University from 1996 to 2000.
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.